Caplin Point Laboratories Limited AI Stock Analysis
Want to see IN:CAPLIPOINT full AI Analyst Report?
Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis
Caplin Point Laboratories Limited
(NSE:CAPLIPOINT)
Caplin Point earns a solid above-average score driven primarily by exceptional fundamentals: a virtually debt-free balance sheet, consistent ~20% return on equity, double-digit revenue growth and industry-leading margins. Offsetting this is poor near-term technical positioning — the stock trades below all key moving averages with negative MACD momentum, though oversold RSI and Stochastic readings suggest selling may be stretched. Valuation at 23x earnings is fair for the growth and quality on offer, while the sub-0.5% dividend yield adds little support. Items to monitor are the forecast slowdown in FY2026 revenue growth and year-to-year volatility in free cash flow conversion tied to capex cycles.
Caplin Point Laboratories Limited (CAPLIPOINT) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 154.24B
- Dividend Yield
- 0.39%
- Average Volume (3M)
- 14.85K
- Price to Earnings (P/E)
- 22.4
- Beta (1Y)
- 1.00
- Revenue Growth
- 16.84%
- EPS Growth
- 17.02%
- Country
- India
- Employees
- 3,406
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Caplin Point Laboratories Limited Business Overview & Revenue Model
Company Description
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive produc...
Caplin Point Laboratories Limited Financial Statement Overview
Summary
Financials are the standout strength. Revenue compounded ~16% annually from ₹10.6B (FY2021) to ₹19.4B (FY2025) with net income more than doubling to ₹5.4B, supported by stable gross margins of 54–59% and net margins of 23–28% (Income Statement: 82). The balance sheet is a fortress — total debt of just ₹50.2M against ₹28.5B equity (D/E ~0.002) and consistently ~20% return on equity (Balance Sheet: 90). Cash flow is solid but less consistent: operating cash flow rose to ₹4.3B in FY2025 with free cash flow recovering to ₹2.4B, though conversion has swung between 29% and 73% of net income due to lumpy capex (Cash Flow: 75). The main watch item is projected FY2026 revenue growth slowing to 7.1% from prior double-digit rates.
Income Statement
82Very PositiveBalance Sheet
90Very PositiveCash Flow
75Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.87B | 21.87B | 19.40B | 16.96B | 14.68B | 12.71B |
| Gross Profit | 11.15B | 10.50B | 11.38B | 9.40B | 7.89B | 6.99B |
| EBITDA | 8.53B | 8.76B | 6.53B | 5.54B | 4.43B | 3.97B |
| Net Income | 6.41B | 6.41B | 5.36B | 4.57B | 3.76B | 3.00B |
Balance Sheet | ||||||
| Total Assets | 40.45B | 40.45B | 32.09B | 26.98B | 21.91B | 17.36B |
| Cash, Cash Equivalents and Short-Term Investments | 10.07B | 10.07B | 9.03B | 7.88B | 6.50B | 5.13B |
| Total Debt | 46.10M | 46.10M | 50.20M | 19.70M | 54.80M | 21.30M |
| Total Liabilities | 4.15B | 4.15B | 3.22B | 3.51B | 2.84B | 2.26B |
| Stockholders Equity | 35.86B | 35.86B | 28.50B | 23.16B | 18.80B | 14.84B |
Cash Flow | ||||||
| Free Cash Flow | 1.60B | 3.37B | 2.41B | 1.73B | 779.00M | 2.46B |
| Operating Cash Flow | 2.54B | 5.85B | 4.32B | 3.18B | 2.72B | 3.37B |
| Investing Cash Flow | -2.99B | -6.45B | -3.35B | -3.20B | -2.18B | -3.77B |
| Financing Cash Flow | -460.10M | -455.90M | -383.20M | -380.70M | -281.70M | -407.10M |
Caplin Point Laboratories Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 2028.80 is below the 20-day moving average (MA) of 2321.06, below the 50-day MA of 2486.08, and below the 200-day MA of 2195.66, indicating a bearish trend. The MACD of -85.06 indicates Positive momentum. The RSI at 27.50 is Positive, neither overbought nor oversold. The STOCH value of 5.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.
Caplin Point Laboratories Limited Peers Comparison
Overall Rating
IN:AKUMS73Outperform
IN:CAPLIPOINT71Outperform
IN:STAR65Neutral
IN:GRANULES59Neutral
IN:PPLPHARMA56Neutral
IN:JUBLPHARMA49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 112.12B | 29.30 | ― | 0.43% | 17.50% | 14.74% | |
| 71Outperform | INR 158.51B | 22.39 | ― | 0.39% | 16.84% | 17.02% | |
| 65Neutral | INR 89.66B | 14.46 | ― | 0.52% | 11.28% | 55.18% | |
| 59Neutral | INR 199.33B | 28.46 | ― | 0.21% | 21.75% | 36.70% | |
| 56Neutral | INR 318.72B | -151.67 | ― | 0.06% | 9.43% | -767.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | INR 148.36B | 56.26 | ― | 0.53% | 18.30% | -44.95% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:CAPLIPOINT | Caplin Point Laboratories Limited | 2028.80 | 122.72 | 6.44% | |
| IN:AKUMS | Akums Drugs and Pharmaceuticals Limited | 696.05 | 283.70 | 68.80% | |
| IN:GRANULES | Granules India Limited | 823.70 | 292.21 | 54.98% | |
| IN:JUBLPHARMA | Jubilant Pharmova Limited | 934.05 | -135.96 | -12.71% | |
| IN:PPLPHARMA | Piramal Pharma Limited | 239.25 | 52.95 | 28.42% | |
| IN:STAR | Strides Pharma Science Ltd | 964.90 | 80.14 | 9.06% |
Caplin Point Laboratories Limited Corporate Events
Caplin Point Laboratories Board Approves Unaudited September 2026 Results
Caplin Point Laboratories Limited’s board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The release also included an investor presentation and a limited review report.Standalo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
